Abstract
The Innovative Medicines Initiative-funded COMBACTE consortium fosters academic-industry partnership in pioneering studies to combat serious bacterial infections. We describe how this partnership is advancing the development of 2 monoclonal antibodies, MEDI4893 and MEDI3902, for the prevention of nosocomial pneumonia.
| Original language | English |
|---|---|
| Pages (from-to) | S46-S51 |
| Journal | Clinical Infectious Diseases |
| Volume | 63 |
| Issue number | Suppl 2 |
| DOIs | |
| Publication status | Published - 15 Aug 2016 |
Keywords
- nosocomial pneumonia
- ventilator-associated pneumonia
- monoclonal antibody
- ICU
Fingerprint
Dive into the research topics of 'The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver